Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M

Krystal Biotech, Inc.

2024-Q1 EPS reported $0.03 revenue$45,250,000

Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.
VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.
Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.
Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.
Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.

Period: the first quarter ending March 31, 2024
Revenue: $45.3 million
Result: reported results

Exact text from the filing

The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.